Compare RSSS & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | COEP |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 91.2M |
| IPO Year | 2008 | N/A |
| Metric | RSSS | COEP |
|---|---|---|
| Price | $2.29 | $16.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 99.4K | 92.3K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.77 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $28,793,922.00 | N/A |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $32.60 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $2.00 | $6.80 |
| 52 Week High | $4.12 | $21.41 |
| Indicator | RSSS | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 72.18 |
| Support Level | $2.16 | $13.77 |
| Resistance Level | $2.66 | $19.19 |
| Average True Range (ATR) | 0.15 | 1.15 |
| MACD | -0.03 | 0.47 |
| Stochastic Oscillator | 38.67 | 87.62 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.